Department of Neurosurgery, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
Thromb Res. 2012 May;129(5):e229-32. doi: 10.1016/j.thromres.2012.01.016. Epub 2012 Mar 3.
Early rebleeding is an important cause of death and disability following aneurysmal subarachnoid haemorrhage (SAH). Recent studies have shown that 50-90% of the rebleedings occurred within the first 6 hours after the primary bleeding. The mechanism leading to rebleeding remains to be established. In the present prospective case-control study we hypothesize that patients with SAH develop a coagulopathy characterized by reduced clot stability during the early period after the initial bleeding.
Patients with aneurysmal SAH was studied with a dynamic clot lysis assay and markers of fibrinolysis and clot stabilizers in blood samples taken within and after 6 hours after onset of bleeding. Results were compared with blood samples from age and gender matched healthy controls.
36 patients were enrolled, 26 patients had blood samples collected within 6 hours after the initial bleeding whereas 10 patients had blood samples taken later than 6 hours after the initial bleeding. Patients demonstrated significantly reduced clot stability during the first 6 hours after initial bleeding. Fibrinolytic activity was increased during the first 6 hours along with the inhibitors of fibrinolysis whereas the modulators of fibrinolysis were reduced or inactivated.
During the first 6 hours after SAH patients exhibit reduced clot-stability. Probably a consequence of activated fibrinolysis in combination with reduced or inactivated factor XIII and thrombin-activable fibrinolysis inhibitor.
蛛网膜下腔出血(SAH)后早期再出血是导致死亡和残疾的重要原因。最近的研究表明,50-90%的再出血发生在初次出血后的 6 小时内。导致再出血的机制仍未确定。在本前瞻性病例对照研究中,我们假设 SAH 患者在初次出血后的早期会出现凝血功能障碍,表现为凝血块稳定性降低。
对发病后 6 小时内和 6 小时后采集的动脉瘤性 SAH 患者的血液样本进行动态凝血溶解试验和纤溶及凝血块稳定剂标志物检测。将结果与年龄和性别匹配的健康对照者的血液样本进行比较。
共纳入 36 例患者,26 例患者在初次出血后 6 小时内采集了血液样本,10 例患者在初次出血后 6 小时后采集了血液样本。患者在初次出血后 6 小时内凝血块稳定性明显降低。纤溶活性在最初的 6 小时内增加,同时纤溶抑制剂也增加,而纤溶调节剂减少或失活。
在 SAH 发生后的最初 6 小时内,患者的凝血块稳定性降低。可能是由于纤溶激活,同时因子 XIII 和凝血酶激活的纤溶抑制剂减少或失活所致。